Anavex Life Sciences Corp (AVXL)

[powerwalker]

Mc,

not all 25 Patients have reached 15 months yet

depending upon which 15 month marker one wants to see (part of the transparency issue with Anavex's reporting). For the 48/53 week reporting sequence, the next reporting period would be 60/65 weeks, which would be 15 months (early December 2016) for the last sign-ups in early September 2015. So Anavex has those scores from the 25 and the trend is known, especially for the converts, so it is possible that Anavex knowingly, and with confidence, states:

Results
Safety: ANAVEX2-73 demonstrated a favorable safety profile in AD patients. The most common AEs were grade 1. Positive unexpected therapeutic response events, such as improved mood, improved social engagement and increased independent activities were recorded.
Exploratory Efficacy: 15-months data demonstrate that ANAVEX2-73 preserves average MMSE and ADCS-ADL scores and shows benefits over baseline for Cogstate and QEEG/ERP.

Conclusion
The safety of ANAVEX2-73 was assessed and MTD was determined. Despite not optimal dosing, both cognitive and functional performance is sustained over at least 12 months, suggesting that the effect of the compound does not seem to worsen AD symptoms with repeated dosing. In a progressive degenerative disease this is considered a positive outcome. The data support further clinical development of ANAVEX2-73 and preparation for a larger confirmatory study is underway.